Cryo-EM Structures of the XPF-ERCC1 Endonuclease Reveal an Auto-Inhibited Conformation and the Basis for Activation

Morgan Jones¹, Fabienne Beuron², Aaron Borg³, Andrea Nans⁴, Christopher Earl¹, David C. Briggs¹, Maureen Bowles¹, Edward P. Morris², Mark Linch³ and Neil Q. McDonald¹,6*

¹Signalling and Structural Biology Laboratory, Francis Crick Institute, NW1 1AT, London, United Kingdom
²Structural Electron Microscopy, The Institute of Cancer Research, SW7 3RP, London, United Kingdom
³Mass Spectrometry Science Technology Platform, Francis Crick Institute, NW1 1AT, London, United Kingdom
⁴Structural Biology of Cells and Viruses, Francis Crick Institute, NW1 1AT, London, United Kingdom
⁵Department of Oncology, University College London Cancer Institute, WC1E 6AG, London, England, United Kingdom
⁶Institute of Structural and Molecular Biology, Birkbeck College, Malet Street, London WC1E 7HX, United Kingdom

For Correspondence: neil.mcdonald@crick.ac.uk

Competing interests: The authors declare that no competing interests exist

Abstract
The structure-specific endonuclease XPF-ERCC1 participates in multiple DNA damage repair pathways including nucleotide excision repair (NER) and inter-strand crosslink repair (ICLR). How XPF-ERCC1 is catalytically activated by DNA junction substrates is not currently understood. We report cryo-electron microscopy structures of both DNA-free and DNA-bound human XPF-ERCC1. DNA-free XPF-ERCC1 adopts an auto-inhibited conformation in which the XPF helical domain masks ERCC1 DNA-binding elements and restricts access to the XPF catalytic site. Binding of a model DNA junction separates the XPF helical and ERCC1 (HhH)₂ domains, promoting activation. Using these structural data, we propose a model for a 5’-NER incision complex involving XPF-ERCC1-XPA and a DNA junction substrate. Structure-function data suggest xeroderma pigmentosum patient mutations often compromise the structural integrity of XPF-ERCC1. Fanconi anaemia patient mutations often display substantial in-vitro activity but are resistant to activation by ICLR recruitment factor SLX4. Our data provide insights into XPF-ERCC1 architecture and catalytic activation.

Introduction
Structure-specific endonucleases (SSEs) are found in all branches of life and play crucial roles in genome repair, replication and recombination¹. These endonucleases act on similar DNA structures with defined polarity but use different catalytic mechanisms. The structurally-related XPF/MUS81 family are an important group of human 3’-nucleases that associate to form two active endonuclease heterodimers (XPF-ERCC1 and MUS81-EME1) and a pseudo-nuclease (FANCM-FAAP24)². XPF-ERCC1 recognises double-stranded/single-stranded (ds/ss) DNA junctions which have a 3’-ssDNA overhang, nicking the dsDNA backbone to produce a substrate for subsequent steps in repair pathways. XPF-ERCC1 activity is essential for removing helical DNA distortions arising from UV-induced damage and bulky adducts as part of the nucleotide excision repair (NER) pathway³. In this context XPF-ERCC1 nicks the damaged DNA strand 5’ of the lesion at the ds/ss junction of an NER repair bubble. It is also required for inter-strand crosslink repair (ICLR), some double-strand break repair processes, base excision repair, Holliday junction resolution, gene-conversion and telomere maintenance⁴-¹⁰. Mutations in XPF and ERCC1 genes are associated with genetic disorders exhibiting diverse phenotypes. These pathologies are caused by defects in the genome maintenance pathways that involve XPF-ERCC1 and include xeroderma pigmentosum (XP), Cockayne’s syndrome, Fanconi anaemia (FA), XPFE progeria and cerebro-oculo-facio-skeletal syndrome¹¹-¹⁵. The genotype-phenotype correlations of XPF-ERCC1 driven diseases are still poorly understood.

XPF is the enzymatically active subunit of the heterodimeric endonuclease and is comprised of a helicase-like module (HLM) and a catalytic module (CM) (Fig. 1a). The XPF HLM is related to the superfamily 2 helicases, with two divergent RecA-like domains that flank an α-helical domain⁶ (Fig. 1a). Both XPF RecA-like domains, termed RecA-like domain 1 (RecA1) and RecA-like domain 2 (RecA2) lack the residues necessary to bind and hydrolyze ATP¹⁷,¹⁸. Instead the HLM is required for full XPF activity and can bind to both the ICLR recruitment factor SLX4 and ds/ssDNA structures¹⁹,²⁰. The XPF CM consists of a nuclease domain containing a metal-dependent GDX ERKXD active site motif and a tandem helix-hairpin-helix termed an (HhH)₂ domain²¹. The smaller ERCC1 subunit has no catalytic activity but is structurally related to the XPF CM, consisting of a nuclease-like domain (NLD) and its own dsDNA-binding (HhH)₂ domain. Both ERCC1 domains heterodimerise with their equivalent domains.
in the XPF CM, forming discrete nuclease-NLD and 2x(HhH)₂ functional units. As well as contributing to XPF stability, ERCC1 binds ds/ssDNA substrates and engages the XPA repair protein that is required for NER recruitment²². Currently there are no available structures of the XPF HLM or of any full-length XPF-Mus81 family members. By solving the structure of a near full-length human XPF-ERCC1 we have defined its overall architecture and uncovered a previously unreported auto-regulatory mechanism. We show XPF-ERCC1 adopts an auto-inhibited conformation in the absence of DNA in order to prevent promiscuous cleavage and provide structural evidence for initial steps in XPF-ERCC1 activation upon binding a DNA junction.

Results
Structure determination of human XPF-ERCC1 endonuclease
A single particle cryo-electron microscopy (cryo-EM) density map of purified recombinant XPF-ERCC1 complex (128kDa) (Fig. 1b) was determined at a global resolution of 4.0 Å (Supplementary Fig. 4b) enabling the assignment of XPF-ERCC1 domain organisation. The map represents the single dominant conformer observed following 3D classification protocols (Supplementary Fig. 3) and exhibits clear secondary structure features throughout (Fig. 1c and 1d). Local resolution analysis indicated that the heterodimeric 2x(HhH)₂ domain dimer exhibited some mobility, so signal subtraction of this domain was carried out followed by local refinement. This process improved the resolution of the resulting sub-volume to 3.6 Å (Supplementary Fig. 4d) which enabled de novo building, refinement and validation of an atomic model (Table 1). The locally-refined map shows clear side-chain density throughout with the local resolution ranging from 3.4 Å in the RecA1 and RecA2 domain cores (Fig. 1c) to 7 Å at the periphery of the ERCC1 NLD. Regions modelled as poly-alanine or omitted from the final structure are shown in Supplementary Table S1. There was no density recovered for the ERCC1 N-terminus, consistent with it being proteolytically cleaved (Supplementary Fig. 1b). Inspection of the angular distribution of assigned particle images during refinement, the 3DFSC curves and 3D flexibility analysis indicate that resolution differences were due to intrinsic flexibility rather than a lack of contributing particle images (Supplementary Fig. 4e-g).

Overall architecture of human XPF-ERCC1 endonuclease
The cryo-EM structure of near full-length XPF-ERCC1 reveals a compact conformation with extensive interactions between the XPF HLM and CM modules (Fig. 2a). Overall, the HLM adopts a “C”-shape that has dimensions of approximately 70Å x 40Å x 60Å. The two RecA-like domains form a rigid platform and lack a nucleotide cleft between them characteristic of many ATP-driven helicases. Instead the two XPF RecA-like domains are linked through the intimate intertwining of secondary structural elements that extend beyond their globular portion. While RecA1 caps one edge of the HLM and engages the XPF nuclease domain in the CM, the helical domain caps the other HLM extremity and engages the CM and the dsDNA-binding ERCC1 (HhH)₂ domain (Fig. 2a). In this manner both ends of the HLM engage crucial elements within the XPF CM and ERCC1, indicating a key regulatory role for the HLM. Interfaces observed in the XPF-ERCC1 structure were largely validated using XL-MS data (Fig. 2b) (Supplementary Table S2). We note that this method requires accessible lysine sidechains therefore predominantly hydrophobic interfaces, such as the RecA1-nuclease, did not return any crosslinks²³.

Structure of the XPF helicase-like module (HLM)
The XPF HLM is typical of other helicase superfamily 2 (SF2) members with a RecA1-helical domain-RecA2 organisation, but with substantial inserts within RecA2. In the absence of ATP binding and hydrolysis motifs or a nucleotide binding cleft, RecA1-RecA2 are linked together through a predominantly polar interface (2007 Å²). Major interface contributions are made by intertwined secondary structural elements ß8 and α20 that form C-terminal extension to RecA1 and RecA2 respectively, as well as the XPF amino-terminus (Supplementary Fig. 5d). The main contacts centre on a π-ring stacking interaction between RecA1 domain Y71XPF and RecA2 domain Y564XPF at one interface edge (Supplementary Fig. 5c) and L39XPF and I592XPF on the other edge. Polar residues make up the remaining contacts with a small cavity. No protein expression was observed for a Y71A_XPF mutant (Table 2). The strand ß8 extends the smaller RecA2 four parallel ß-stranded sheet while α20 packs against the larger RecA1 seven-stranded parallel beta sheet (ß1–ß7). The observed structural rigidity of the RecA1-RecA2 unit is structurally homologous to equivalent domains in nucleosome-bound chromatin remodelers ISW1 and INO80²⁴,²⁵. XPF RecA2 has two large inserts with unknown functions (Fig. 1a). Insert one (residues 345-377) separates the helical and RecA2 domains and insert two (residues 441-550) interrupts the RecA2 fold. There is sufficient density in our map to trace the backbone of residues 345-362 and 366-377 from insert one projecting away from the body of the structure. However, no density was recovered for insert two, consistent with predictions that this region is likely intrinsically disordered in the absence of DNA. Cross-linking mass spectrometry (XL-MS) data iden-
tified a large number of intra-insert crosslinks within inserts one and two, consistent with these highly basic regions being flexible (Supplementary Table 1).

The XPF helical domain is an integral part of the HLM and folds as a five anti-parallel helical bundle. This domain packs tightly against RecA2 in a conformation stabilised by the interactions between D302^XPF and Q419^XPF, and Q300^XPF and S412^XPF (Supplementary Fig. 5b). The Q300A^XPF mutant significantly reduces XPF-ERCC1 expression and increases aggregation (Table 2). Helix α17 (residues 426-440) also contributes to tethering the helical domain to RecA2. The observed position of the helical domain determines the orientation and angle of the extended RecA2 C-terminal α20 helix (Supplementary Fig. 5d), stabilising the HLM conformation through interaction between Q226^XPF and T614^XPF.

The closest structural homologue identified by DALI protein structural comparison server²⁶ is the helicase/
figure 2. architecture of the XPF helicase-like module and coupling with the catalytic module. a upper panel, view of the XPF-ERCC1 structure showing how the helicase-like module (HLM), displayed using surface rendering forms a “C”-shaped structure and contacts the XPF nuclease domain at two interfaces and the ERCC1 (HhH)2 domain, each shown as a cartoon. Domains are coloured according to the scheme used in Fig. 1a. Middle left panel, interaction between H275 in the XPF helical domain (green) and S730 in the XPF nuclease domain (gold). Blue lines indicate hydrogen bonds. Middle right panel, hydrophobic interaction interface between XPF RecA2 (blue) and nuclease (gold) domains. Lower right panel shows an orthogonal view and interaction between E317 in the XPF helical domain (green) and T252 in the ERCC1 (HhH)2 domain.

b cartoon schematic representing inter-domain crosslinks detected by mass spectrometry. Each black line indicates a single unique crosslink between residues in different domains. Domains within the pink ellipsoid form the HLM, whereas domains within the catalytic module and ERCC1 are within the pale blue ellipsoid. c left panel shows XPF HLM and basic residues lining a concave surface that could potentially bind to dsDNA. Right panel is an equivalent view of the helicase module from MDA5 (PDB code: 4GL2) bound to dsRNA through the same positively charged concave surface.
Auto-inhibitory elements within the helical domain regulate XPF-ERCC1 activity

The XPF HLM is coupled to the CM through contacts from RecA1 and the helical domain (Fig. 2a). RecA1 forms a substantial interface (1684 Å²) with the XPF nuclease domain involving aromatic and hydrophobic residues from RecA1 ø5 and ø6 helices and XPF nuclease domain ø4 and ø21 helices and ø14 strand (Fig. 2a). The hydrophobic nature of the contact suggests that anchoring of the HLM to the XPF nuclease domain through RecA1 forms a obligate part of the XPF-ERCC1 architecture.

The XPF helical domain forms a contact with the XPF nuclease domain that sterically prevents the ds/ssDNA substrate from reaching the XPF active site (Fig. 2a). A key contact within this auto-inhibited conformation is between sidechains of H275 formerly and S730 formerly (Fig. 2a, middle panel), the latter sidechain also forms multiple hydrogen-bonds to the mainchain backbone of the helical domain. A H275 formerly, W274 formerly double mutant, likely to disrupt this contact, displays a 1.5-fold increase in catalytic efficiency relative to the wild-type (Table 2). A second auto-inhibitory interface exists between the XPF helical domain and the ERCC1 (HhH) formerly domain (Fig. 2a, lower panel). This interface is formed through predominantly polar contacts involving the highly conserved T248erccc1 and T252erccc1 residues, the latter of which forms a hydrogen bond with E317xpf. Previous structural and biochemical data suggest that the ERCC1 (HhH) formerly domain binds dsDNA through hairpin residues S244erccc1-N246erccc1 and G276erccc1-G278erccc1 mainchain atoms formerly. These motifs are proximal to T248erccc1 and T252erccc1, and are not accessible in the DNA-free conformation of XPF formerly. The E317A formerly mutant displays a 1.5-fold higher catalytic efficiency than the wild-type likely due to the disruption of this auto-inhibitory interaction (Table 2). Equally, shortening the connecting linker between the XPF nuclease-and (HhH) formerly domain would be predicted to shift the 2x(HhH) formerly unit towards the nuclease domain. Indeed, a similar effect is observed for a 829-833Δxpf mutant displaying a modest 1.2-fold increase in catalytic efficiency and a 7.5-fold tighter Km relative to wild-type.

XPF catalytic module heterodimerises with ERCC1 through two distinct interfaces

ERCC1 is intimately coupled to the XPF CM through two obligate dimerisation surfaces at the equivalent domains of each molecule (Fig. 1e). The XPF nuclease domain uses a helix-strand-helix motif (a25-ß19-a26) to heterodimerise with the equivalent surface of the ERCC1 NLD (a3-ß8-a4) forming a kidney-shaped dimer with an extensive interaction interface (1684 Å²) (Supplementary Fig. 5a). The contact is predominantly hydrophilic and is flanked by three salt-bridges (Supplementary Fig. 5a). This interface uses equivalent elements to those mediating heterodimerisation of homologous domains from Mus81-Eme1 and FANCM-FAAP24 complexes 31,32. The observed interaction contradicts a previous report arguing against heterodimerisation of the XPF nuclease domain-ERCC1 NLD unit 30. We note that the XPF (HhH) formerly domain hetero-dimerises with the ERCC1 (HhH) formerly domain through predominantly hydrophobic contacts close to F851formerly and F900formerly as previously observed 30,33. The (HhH) formerly domain from XPF and ERCC1 are connected to their XPF nucleoase domain/ERCC1 NLD domain through ordered linker sequences. There is sufficient density in our cryo-EM map to trace the backbone for both linkers (Fig. 1e). The ERCC1 linker makes unexpected interactions with the XPF nuclease domain via Y215 formerly-CC1 and D221 formerly-CC1 (Fig. 3b). We note that Y215 formerly-CC1 lies adjacent to S786formerly suggesting the FA mutation S786 formerly would disrupt this contact with ERCC1.

Structural environment and differential impact of XP and FA patient mutations

Recruitment of XPF-ERCC1 into either NER or ICLR pathway complexes is dependent on interaction with partner proteins XPA or SLX4 at their respective damaged DNA structures (Fig. 3a). A previous study mapped the XPA-binding site to a cleft within the ERCC1 NLD formerly (Fig. 3a). This interaction is spatially distinct from the proposed SLX4 site centred within the helical domain at L230formerly 19. Insights from disease-mutations have shown that repair pathway recruitment can be disrupted by separation-of-function (FA) or partial loss-of-function (XP) mutations, however the structural basis for this is unclear 35.

With the availability of a three-dimensional XPF-ERCC1 structure, it was possible to explore the location and structural environment of disease-causing muta-
tions and correlate this with their impact on enzyme stability and catalytic activity. Patient-derived XP or FA associated mutations were characterised in-vitro using a previously reported fluorescence incision assay. Mutations associated with XP mapped primarily to the XPF RecA2 domain and its inserts. L608\textsubscript{XPF}, R589\textsubscript{XPF} and T567\textsubscript{XPF} are located in the folded region of the RecA2 domain, with the latter two forming structurally important intra-domain contacts\textsuperscript{36} (Fig. 3c). Indeed, L608\textsuperscript{XP} and T567\textsuperscript{XP} mutant proteins formed soluble aggregates when expressed recombinantly, as measured by analytical size exclusion chromatography (data not shown), and an R589\textsuperscript{XP} mutant exhibited 35-fold reduction in catalytic efficiency (Table 2). The R799W\textsuperscript{XP} XP mutation failed to express recombinantly and lies on the periphery of the

Fig. 3 Mapping XPF-ERCC1 disease mutations and DNA repair pathway recruitment sites a Ribbon model of XPF-ERCC1 highlighting the spatially distinct binding sites of XPA and SLX4. XPA binds to the ERCC1 NLD (coral) and SLX4 binds to the XPF helical domain (green). The XPA peptide (residues 66-77) atoms are displayed as red spheres (PDB: 2JNW). The key SLX4 binding residue L230 sidechain atoms are also displayed as red spheres. The DNA repair structures targeted by XPF-ERCC1 by recruitment through SLX4 (interstrand crosslink) or XPA (intrastrand crosslink) are shown. b-d The molecular environment of patient-derived disease mutations are indicated. Residues associated with patient mutations are displayed with ball and stick rendering and selected neighbouring residues are also shown as sticks. Residue colouring indicates the diseases associated with mutation of that residue: Red – Fanconi anaemia, Black – xeroderma pigmentosum. b Mutations in the XPF nuclease domain and ERCC1 NLD give rise to both Fanconi anaemia and XP. c XP associated mutations disrupt key structural contacts in the XPF RecA2 domain. d Fanconi anaemia associated mutations cluster in the XPF helical domain. The helical domain also contains the XP associated mutant, I225.
heterodimeric nuclease-NLD interface with ERCC1 (Fig. 3b). These data, taken in the context of our structure, suggest the L608P\textsuperscript{XP}, T567A\textsuperscript{XP}, R589W\textsuperscript{XP} and R799W\textsuperscript{XP} XP disease mutants compromise XPF-ERCC1 structural stability. I225\textsuperscript{XP} in the helical domain (Fig. 3d) is also associated with XP but does not appear to contribute to XPF-ERCC1 structural stability\textsuperscript{15}.

FA patients are proficient in NER but deficient in ICLR, indicating a separation of function\textsuperscript{19,38}. FA point mutations within XPF including L230R\textsuperscript{XP}, C236R\textsuperscript{XP} and G325E\textsuperscript{XP} cluster in the XPF helical domain\textsuperscript{11} (Fig. 3d). These mutants, when expressed recombinantly, were found to have a similar level of endonuclease activity against a stem-loop substrate to wild-type XPF-ERCC1 (Table 2). SLX4 has been shown to stimulate XPF-ERCC1 activity and recruit the endonuclease to ICLR sites ex-vivo\textsuperscript{19}. In order to determine whether FA mutants display differences in activity in the presence of SLX4, an XPF-ERCC1-SLX4\textsuperscript{NTD} complex was assembled and its activity determined\textsuperscript{39,40} (Supplementary Fig. 11d). We found that the binding of SLX4\textsuperscript{NTD} to wild-type XPF-ERCC1 stimulated its endonuclease activity, increasing the catalytic efficiency approximately 6-fold (Table 3). However, binding of SLX4\textsuperscript{NTD} to FA mutant 323-326Δ\textsuperscript{XP} decreased the catalytic efficiency approximately 5.5-fold relative to wild-type XPF-ERCC1 in the absence of SLX4 (Table 3), suggesting that a subset of FA mutants are insensitive to SLX4 activation. FA mutant L230R\textsuperscript{XP} was unable to bind SLX4\textsuperscript{NTD} (data not shown). This is consistent with a previous study that used full-length SLX4, indicating that it forms a key determinant of the SLX4 binding site\textsuperscript{19}. Mutations that disrupt the SLX4 binding site of XPF-ERCC1 are likely to underpin FA disease by preventing recruitment to ICLR sites.

Evidence for XPF-ERCC1 conformational activation driven by DNA junction binding

The auto-inhibitory interactions formed by the XPF helical domain were hypothesised to be released following XPF-ERCC1 DNA junction engagement and prior to the incision reaction. To probe the nature of such potential conformational changes, we assembled a complex of XPF-ERCC1 bound to a DNA stem-loop substrate (10-duplex 20-T single-strand stem-loop) that we previously showed presents a single incision site to XPF-ERCC1\textsuperscript{120}. Using an electrophoretic mobility shift assay (EMSA) we observed 1:1:1 stoichiometric binding of the stem-loop DNA to XPF-ERCC1 (Supplementary Fig. 6).

This sample was used for cryo-EM data collection leading to a single particle cryo-EM density map at a global resolution of 7.7 Å. This reconstruction enabled the placement of all XPF-ERCC1 domains using the DNA-free structure as an initial template (Fig. 4a). Signal subtraction of the dimeric 2x(HhH)\textsubscript{2} domain and DNA density, followed by local refinement, improved the resolution of the resulting sub-volume to 5.9 Å (Supplementary Fig. 9c; Table 1). Comparison of both maps enabled the identification of the duplex portion of the stem loop based on the density for two strands and a concave surface of a dsDNA major groove (Fig. 4b). This enabled a DNA-bound XPF-ERCC1 structure to be built that revealed substantial conformational rearrangements uncoupling the XPF HLM from the CM. The greater conformational variability observed in the DNA-bound structure, compared to the DNA-free complex, is likely to have limited the resolution and may reflect the absence of stabilising recruitment factors or the need for longer DNA junction substrates.

The most striking changes to the XPF-ERCC1 structure following DNA binding involve the XPF helical and 2x(HhH)\textsubscript{2} domains, consistent with an opening of the HLM and stem-loop engagement by the CM (Fig. 4c). The RecA1-RecA2 unit remains structurally rigid, with high-resolution features present in 2D class averages, whereas the rest of the complex increased in flexibility (Supplementary Fig. 7b). The interface between the XPF RecA1 and nuclease domains also remains intact. The resolution ranges from 7 Å in the core of the RecA1-RecA2 unit to 12 Å in the ERCC1 NLD (Supplementary Fig. 9a). Additional density is apparent adjacent to the RecA2 β-sheet and could represent part of the missing insert two, analogous to a dsRNA-binding region of MDA5.

Comparison with the DNA-free structure reveals that the XPF helical domain pivots by approximately 15°, rotating ~11 Å away from the nuclease domain (Fig. 4c and Supplementary Fig. 10a). This conformational change breaks the autoinhibitory contact formed between H275\textsuperscript{XP} and S730\textsuperscript{XP}. The positioning of the XPF α17 helix acts as a steric brake, preventing the HLM from adopting an open conformation capable of binding dsDNA\textsuperscript{27} (Supplementary Fig. 10b). The most dramatic difference in the DNA-bound conformer is the displacement of the dimeric 2x(HhH)\textsubscript{2} domain by 47 Å, detaching from the XPF helical domain to contact the XPF nuclease - ERCC1 NLD unit (Fig. 4c). The RecA1-RecA2 unit remains structurally rigid, with high-resolution features present in 2D class averages, whereas the rest of the complex increased in flexibility (Supplementary Fig. 7b). The interface between the XPF RecA1 and nuclease domains also remains intact. The resolution ranges from 7 Å in the core of the RecA1-RecA2 unit to 12 Å in the ERCC1 NLD (Supplementary Fig. 9a). Additional density is apparent adjacent to the RecA2 β-sheet and could represent part of the missing insert two, analogous to a dsRNA-binding region of MDA5.

The ERCC1 (HhH)\textsubscript{2} domain engages the dsDNA through the minor groove by hairpin residues S244\textsuperscript{ERCC1},N246\textsuperscript{ERCC1} and G276\textsuperscript{ERCC1}-G278\textsuperscript{ERCC1} main-chain atoms, similar to a previous structure of A. pernix XPF bound to dsDNA\textsuperscript{29}. In this configuration the
dimeric 2x(HhH) domain lies proximal to the ERCC1 NLD domain, pairing up both known ssDNA-binding elements of the endonuclease (ERCC1 NLD and XPF (HhH) domain) (Fig. 4d). Others have proposed that XPF-ERCC1 2x(HhH) domain is sufficient to recognise ds/ssDNA junctions, however the pre-
cise arrangement of multiple ssDNA and dsDNA domains required for DNA junction recognition remains to be determined. The final DNA-bound model lacks the single-stranded portion of the stem loop and places the scissile phosphodiester bond approximately 15 Å from the XPF active site motif (residues 725-727). We interpret the DNA-bound structure as showing important features of an initial step towards full DNA junction recognition prior to the incision reaction. The low resolution of the DNA component within the cryo-EM map (approximately 9 Å) suggests that the dimeric 2x(HhH)₉-DNA complex can adopt multiple conformers. Equally, the accessibility of the dsDNA major groove opposite to the 2x(HhH)₂ minor groove interaction could be re-oriented towards the positively charged concave surface within the XPF HLM, analogous to how MDA5 recognises dsRNA (Fig. 4e).

Towards a complete model for nucleotide excision repair 5’-incision complex

While this manuscript was in preparation, the structure of a ds/ssDNA-bound TFIIH-XPA (PDB code: 6RO4) was published representing a 5’-NER pre-incision complex that XPF-ERCC1 is known to engage⁴⁵. We therefore sought to build a full model for an NER 5’-incision complex, by docking our DNA-bound XPF-ERCC1 conformer onto the structure of ds/ssDNA-bound TFIIH-XPA. To do this we superimposed the ERCC1 (HhH)₂ domain-dsDNA complex onto the exposed DNA minor groove at the ds-ssDNA junction (Fig. 4f) noting a remarkable non-overlapping complementarity in DNA binding with XPA. ERCC1 engaged precisely the available DNA elements that were not engaged by XPA (Fig. 4g). The endonuclease activity of XPF-ERCC1 nicks two nucleotides into the duplex portion of a model stem-loop²⁰. As XPF-ERCC1 lacks an obvious “wedge” to separate dsDNA near discontinuities, but has both dsDNA and ssDNA binding functions, it is possible that XPA and SLX4 serve in this capacity in NER and ICLR respectively. Consistent with this XPA utilises a β-hairpin element to separate dsDNA individual strands and demarcates the 5’-edge of the repair bubble⁴⁵.

The 5’-incision complex model also anticipates several extensive interfaces between the XPF-ERCC1 and TFIIH-XPA-DNA structures and contained surprisingly few steric clashes, all of which were within the flexible XPA loop region (residues 104-131) (Fig. 4f). In this model, the dimeric 2x(HhH)₂ domain lies adjacent to the TFIIH subunit XPB and DNA whilst the XPF nuclease-ERCC1 NLD dimer is positioned close to XPD, XPA and DNA. The highly basic and flexible RecA2 insert one (residues 345-377) is oriented to interact with either the extended XPA helix or dsDNA. The flexible regions of the XPF-ERCC1-DNA map correspond to those domains proposed to make extensive TFIIH-XPA-DNA interactions. It is therefore likely that these interfaces become stabilised upon TFIIH-XPA-DNA binding. Further experiments to validate these contacts by XL-MS are required.

Discussion

The structural and functional studies described in this report provide new insights into XPF-ERCC1 architecture, regulation and activation. This XPF-ERCC1 endonuclease catalyses the first irreversible step in NER repair by nicking the 5’-edge of the repair bubble structure on the damaged strand. The structure of DNA-free XPF-ERCC1 reveals how the heterodimer is auto-inhibited by blocking both DNA binding and active site access through contacts with the XPF helical domain. This structure reveals inter-domain interfaces not previously described and rationalises our previous report that the HLM impacts on endonuclease activity and substrate interaction²⁰. It also confirms the presence of a heterodimeric interface between the XPF nuclease and ERCC1 NLD as described for other family members²⁹,³¹,³².

This study provides evidence linking conformational activation of XPF-ERCC1 through its recruitment by partner proteins to DNA junction sites prepared for either NER or ICLR pathways (Fig. 3a). Mapping the XPA interaction site within ERCC1³⁴ and the SLX4 site within XPF helical domain reveals spatial separation of each recruitment partner site in the auto-inhibited state. It suggests the critical binding determinants are non-overlapping, but full structures of XPF-ERCC1 with SLX4 or XPA combined with competition binding studies are required to prove this. XPF-ERCC1 activation by SLX4 is disrupted by some FA mutations that map to the helical domain, in agreement with previous in-vivo work¹⁹,³⁸. Given its proposed regulatory role, the helical domain may be repositioned on binding SLX4 to stimulate activity³⁹,⁴⁰. In contrast, XP associated mutations were found to generally reduce endonuclease activity in-vitro towards an NER substrate by destabilising the complex whereas FA mutants exhibited activity similar to wild-type.

XPF-ERCC1 cryo-EM structures described here reveal how engagement with a DNA junction substrate is able to disengage the XPF helical domain from the XPF CM and release the heterodimeric 2x(HhH)₂ domain. The released 2x(HhH)₂ domain is then able to engage a minor groove in the DNA duplex adjacent to the DNA ds/ss junction and packs against the XPF nuclease - ERCC1 NLD dimer, as observed for structures of Mus81-Eme1 and A. pernix XPF. In-silico
docking of the DNA-bound conformation of XPF-ERCC1 onto the recent TFIIH-XPA-DNA structure permits the assembly of a model for a NER 5’-incision complex. The model is consistent with the ERCC1 (HhH)2 hairpins engaging the minor groove and XPA the major groove of a DNA substrate. This positions the XPF hairpins to bind ssDNA and the nuclease domain for cleavage of substrates with the correct polarity.

The structures described here do not reveal the full basis for DNA junction recognition or the extent of conformational flexing required to place the scissile bond proximal to the XPF catalytic centre. We speculate that the similarities between XPF HLM and the MDA5 helicase point to a concave surface that could engage the major groove of the dsDNA element of a DNA junction to promote movement of the ds-ssDNA discontinuity into the XPF catalytic site. Evidently further high-resolution structures are required with longer DNA substrates and recruitment partner complexes in order to fully understand how the scissile phosphodiester bond is presented to the XPF catalytic site and the extent of the conformational alterations required.

There is a pressing need to explore opportunities for chemical inhibition of XPF-ERCC1 in view of the XPF synthetic lethality with the DNA translocase FANCM, particularly relevant to FANCM-deficient tumours44 and also with PARP inhibition45. The availability of an atomic structure for human XPF-ERCC1 described here will encourage such efforts to develop new precision medicines as well as to overcome cancer chemoresistance46.

### Tables

**Table 1.** Cryo-EM statistics for XPF-ERCC1 structures and associated maps

| Protein      | Mutant | Rationale       | k_{max} \text{(fmo/lmin)} | k_{cat} \text{ (s^{-1})} | k_{cat}/k_{m} \text{ (nM^{-1} min^{-1})} |
|--------------|--------|-----------------|---------------------------|--------------------------|------------------------------------------|
| XPF          | WT     |                 | 104.7 ± 2.8              | 12.1 ± 1.4               | 20.9 ± 0.66                              |
| XPF          | L230R  | FA              | 65.2 ± 2.1               | 8.1 ± 1.1                | 130.3 ± 3.3                              |
| XPF          | L236R  | FA              | 91.2 ± 2.6               | 10.8 ± 2.1               | 8.25 ± 0.5                               |
| XPF          | E239K  | FA              | 88.9 ± 4.7               | 12.4 ± 2.1               | 16.9 ± 0.7                               |
| XPF          | S786F  | ICLR deficient  | 80.9 ± 3.8               | 32.5 ± 1.5               | 7.9 ± 0.8                               |
| XPF          | 323-326 | ICLR deficient  | 120.2 ± 1.4              | 20.5 ± 0.8               | 42.4 ± 0.3                               |
| XPF          | E317A  | Autobinhibiton  | 193.4 ± 8.6              | 15.2 ± 2.4               | 38.7 ± 1.3                               |
| XPF          | R121A  | DNA-binding     | 24.5 ± 1.1               | 4.32 ± 0.3               | 56.2 ± 0.2                               |
| XPF          | 829-833 | Autobinhibiton  | 20.2 ± 0.5               | 1.9 ± 0.2                | 38.2 ± 0.8                               |
| XPF          | R589W  | XP              | 8.22 ± 2.6               | 25.9 ± 6.1               | 0.62 ± 0.1                               |
| XPF          | Q300A  | Structural       | N/A                       | N/A                      | N/A                                      |
| ERCC1        | L253A  | Autobinhibiton  | 33.1 ± 2.7               | 28.7 ± 22.3              | 3.4 ± 0.3                                |

**Table 2.** Kinetic data for selected XPF-ERCC1 mutations

| Protein      | Mutant | Rationale       | k_{max} \text{(fmo/lmin)} | k_{cat} \text{ (min^{-1})} | k_{cat}/k_{m} \text{ (nM^{-1} min^{-1})} |
|--------------|--------|-----------------|---------------------------|---------------------------|------------------------------------------|
| XPF-ERCC1-SLX4\text{NTD} | WT     |                 | 219.2 ± 9.3              | 4.3 ± 0.7                | 43.8 ± 1.1                               |
| XPF-ERCC1-SLX4\text{NTD} | 323-326 |                 | 49 ± 6.5                 | 32.2 ± 9.6               | 9.8 ± 1.4                               |

**Table 3.** Activation of XPF-ERCC1 by SLX4\text{NTD} and disruption by mutation

### Methods

**XPF-ERCC1 expression, purification and complex assembly**

All reagents purchased from Sigma-Aldrich unless otherwise stated. A pFastBac Dual vector containing full length, wild type, human XPF (NCBI reference sequence: NM_005236.2) and ERCC1 (NCBI reference sequence: NM_001166049.2) cDNA was modified to include a C-terminal ERCC1 dual strep-tag using restriction enzyme cloning. This plasmid was transformed into competent DH10BAC E. coli cells (Thermo-Fisher) and recombinant baculoviruses expressing XPF and ERCC1 were generated using standard protocols47 (Oxford Expression Technologies). In short, 1x10^6 SF21 cells (Thermo-Fisher) grown in SFFIII media (Thermo-Fisher) and 10 μg/ml gentamycin (Life Technologies) were infected at a multiplicity of infection (MOI) of 2 and harvested after 72 h. Cell pellets were resuspended in extract buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 10% glycerol, 2mM MgCl\text{2}, 0.01% (w/v) 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate (CHAPS), 0.25 tablet of EDTA-free protease-inhibitor cocktail per litre of culture, and 1 μl per 250 mL lysate BaseMuncher (Expedeon) and lysed by sonication. The lysate was cleared of insoluble cell debris by centrifugation at 35,000g for 45 min and incubated with Strep-tactin resin (GE Healthcare) for 1 h at 4 °C. The resin was extensively washed with extract buffer minus protease in-
hibitors and BaseMuncher and incubated for 12 h with Tobacco Etch Virus (TEV) protease (in-house). The eluate, containing XPF-ERCC1 was concentrated and further purified using anion-exchange (HiTrap-Q, GE Healthcare) before a final size exclusion chromatography (SEC) step using a Superdex-200i column (GE Healthcare) in cryo buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 1 mM TCEP, 0.01% (w/v) CHAPS). Mutants were cloned using the Q5 site-directed mutagenesis kit (NEB) and were then expressed using the same protocol as described above for wild type XPF-ERCC1.

**XPF-ERCC1 DNA complex assembly**

DNA with a modified phosphorothioate backbone (SLp DNA) was resuspended in DNA resuspension buffer (10 mM Tris, pH 7.8, 1 mM EDTA and 75 mM NaCl) and annealed to form a stem-loop structure. Purified XPF-ERCC1 was buffer exchanged into XPF-ERCC1 DNA cryo buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 1 mM TCEP, 0.01% (w/v) CHAPS, 5 mM CaCl₂, 0.5 mM EDTA) and then incubated with SLp DNA at a 1:2 protein:DNA molar ratio for 10 mins at 4°C followed by crosslinking with 0.05% (v/v) glutaraldehyde for 10 mins at 4°C. The crosslinking reaction was quenched by the addition of 1 mM Tris-HCl, pH 7.8 and the complex further purified via SEC using a Superdex 200i column. Stem-loop sequence: CAGCGC*T*U*G*G*T*TTTTTTTTTTTTTTTTTTTTTTTTTTT*C*C*A*A*G*CGCTG, where the asterisk * represents a phosphorothioate backbone.

**XPF-ERCC1 cryo-EM grid preparation and data collection**

For cryo-EM analysis, 4 μl of the purified XPF-ERCC1 heterodimer at 1.5 mg/ml was applied to both R1.2/1.3 400 mesh Quantifoil® grids that had been previously glow-discharged for 45 s at 42 mA. The grids were blotted for 4 s at 100% humidity and 4°C and plunged into liquid ethane cooled by liquid nitrogen using a FEI Vitrobot MK IV. The grids were then loaded onto a Titan Krios transmission electron microscope operated at 300 kV (Thermo-Fisher). Images were collected in counting mode using a Gatan K2 Summit direct electron detector camera mounted behind a GIF Quantum energy filter operating in zero-loss mode. Exposures were 15 s, with a total dose of 63 e-/Å² dose-fractionated into 40 frames with a calibrated pixel size of 1.38 Å. Images were recorded with a defocus of 1.5 μm to 4 μm. A total of 15,315 micrographs were collected from three separate data collection sessions.

**XPF-ERCC1 cryo-EM image processing**

Movie frames were corrected for motion using MotionCOR2⁴⁸, and contrast transfer function was estimated using CTFfind4.1⁴⁸ within Scipion-1.2⁵⁰. The total number of movies collected across three collections was 15,315, of which 14,453 were used. 200 micrographs were selected from the first collection from which 82,412 particles were picked using Xmipp3⁵¹ semi-automated picking and extracted using RELION-3⁵². The particles were sorted using Xmipp3⁵¹ screen particles followed by three rounds of reference-free 2D classification in CryoSPARC-2⁵³. A subset of six 2D classes were selected that represented different views of the molecule and used as templates for reference-based particle picking using Gautomatch⁵⁴ on the full dataset. This approach yielded 396,106, 1,201,881 and 2,391,900 particles for data collection runs one, two and three respectively. The particles were extracted and binned two-fold using RELION-3⁵², sorted using Xmipp3⁵¹ screen particles and then submitted for three rounds of reference-free 2D classification in CryoSPARC-2⁵³. This reduced the particle numbers to 151,412, 390,007 and 1,074,111 particles for data collection runs one, two and three respectively. Four initial models were generated using the ab initio reconstruction program in CryoSPARC-2⁵³ and were used as references for 3D classification using heterogeneous refinement in CryoSPARC-2⁵³. Multiple rounds of heterogeneous refinement yielded 44,312, 126,492 and 390,712 particles in well-defined classes for data collection runs one, two and three respectively. All 561,516 particles from the three collections were re-extracted in an un-binned 200 x 200-pixel box using RELION-3⁵² and merged. The data then underwent 3D classification without alignment in RELION-3⁵² to identify the most stable, high-resolution class. The two classes that displayed the highest-resolution features, comprising 405,339 particles, were refined to 4.1 Å resolution in CryoSPARC-2⁵³ using non-uniform refinement. Per-particle motion corrected was carried out using Bayesian polishing in RELION-3⁵². The shiny, polished particles were then refined to 4.0 Å resolution in CryoSPARC-2⁵³ using non-uniform refinement.

Inspection of the 4.0 Å resolution map rendered by local refinement in UCSF Chimera⁵⁵ identified the dimeric XPF-ERCC1 2x(HhH)₂ domain as the lowest resolution region of the map, suggesting some degree of mobility. A mask which excluded the low-resolution XPF-ERCC1 2x(HhH)₂ was generated in Chimera⁵⁵ and using the particle subtraction tool in CryoSPARC-2⁵³ the portion of the particle images aligning to the hairpin density in the map was removed. Non-uniform local refinement in CryoSPARC-2⁵³ was performed on the subtracted particles, re-aligning them to the masked reference volume, leading to a reconstruction at 3.6 Å resolution which excluded the hairpin portion of the 4.0 Å map.

All resolutions reported here were determined by Fou-
rrier Shell Correlation (at FSC = 0.143) based on the ‘gold-standard’ protocol using a soft mask around the complex density\(^{53}\). To avoid over-masking, the masked maps were visually inspected to exclude the possibility of the clipping of electron densities. Additionally, the occurrence of over-masking was monitored by inspecting the shapes of FSC curves. The two half maps had their phases randomised beyond the resolution at which the no-mask FSC drops below the FSC = 0.143 criterion. The tight mask is applied to both half maps, and an FSC is calculated. This FSC is used along with the original FSC before phase randomization to compute the corrected FSC. Local resolution was calculated using Bricles within CryoSPARC-2\(^{53}\). For visualisation, maps were sharpened by applying an automated local-resolution weighted negative B factor using the local filtering function of CryoSPARC-2\(^{53}\).

**XPF-ERCC1 model building**

Initially the crystal structures of the ERCC1 nuclease-like domain (NLD) (PDB code: 2A1I) and the tandem helix-hairpin-helix domains comprising XPF and ERCC1 chains (PDB code: 2A1J) were rigid body fitted into the locally-filtered and sharpened map obtained at 4.0 Å resolution. Homology models were generated for the XPF RecA1 domain using Phyre2 and rigid body fit into the map using the same procedure. Subsequently the fitted domains were rebuilt manually using COOT\(^{57}\) optimising the fit where sidechain densities were evident prior to using FlexEM\(^{58}\) and real-space refinement as implemented in PHENIX\(^{59}\) whilst imposing secondary structural and geometric restraints prevent overfitting. The RecA2 and helical domains were built de novo and subjected to PHENIX\(^{59}\) real-space refinement. A further 6 cycles of rebuilding and refinement in COOT\(^{57}\) and PHENIX\(^{59}\) lead to a model containing 743 residues from XPF and 195 from ERCC1. Linkers regions connecting the XPF nuclease and ERCC1 NLD domains to their respective (HhH)\(_2\) domains were built manually into the map and the N-terminal portion of the XPF nuclease domain homology model was rebuilt in COOT\(^{57}\) to fit the map. The final atomic model was evaluated using MolProbity\(^{60}\).

**XPF-ERCC1-DNA complex cryo-EM grid preparation and data collection**

XPF-ERCC1-DNA complex was concentrated to 1.3 mg/ml and applied to Quantifoil R1.2/1.3 300 mesh copper grids. The freezing and imaging conditions used were the same as for the DNA-free XPF-ERCC1 complex described above and 8965 movies were collected.

**XPF-ERCC1-DNA complex cryo-EM image processing**

Motion correction and CTF estimation was performed as previously described for the XPF-ERCC1 data collections. 7982 micrographs were manually selected for processing. Particle picking was carried out as described for the XPF-ERCC1 data collections. 3,432,565 particles were extracted and sorted using Xmipp\(^{51}\) screen particles and then submitted for six rounds of reference-free 2D classification in CryoSPARC-2\(^{53}\). 688,821 particles were used to generate 4 ab initio reconstructions which were then used as references for 3D classification using heterogeneous refinement in CryoSPARC-2\(^{53}\). Multiple rounds of heterogeneous refinement were carried out yielding one well-ordered reconstruction comprising 199,022 particle images. This class was refined to 7.7 Å resolution using non-uniform refinement in CryoSPARC-2\(^{53}\). A mask was generated using UCSF Chimera\(^{55}\) that excluded both the DNA and hairpin domain density which was used to carry out masked refinement improving the resolution of the sub-volume to 5.9 Å.

**XPF-ERCC1-DNA complex model building**

Individual domains of XPF-ERCC1 were taken from the DNA-free structure and fitted into the DNA-bound cryo-EM map density as rigid bodies using the UCSF Chimera\(^{55}\) fit-in-map tool. The nuclease domain dimer of the A. pernix XPF homolog (PDB:2BGW) bound to dsDNA was fitted into the DNA-bound map density and the subsequent position of the DNA-bound A. pernix hairpins used as a reference to align the human hairpin domain using MatchMaker in UCSF Chimera\(^{55}\). The DNA from the A. pernix structure was reduced to a 10 base-pair duplex and modelled into the map whilst preserving the hairpin domain-DNA contacts. The sequence conservation of the functional human ERCC1 and A. pernix (HhH)\(_2\) domains is high: 25.5% identical and 69.1% similar residues. The ds-RNA bound structure of MDA5 was placed into the DNA-bound map density as a guide to place the helical domain of XPF by inspecting the position of the homologous domain in MDA5.

**XPF-ERCC1-DNA-TFIIH-XPA complex modelling**

The XPF-ERCC1-DNA structure was aligned to the TFIIH-DNA-XPA structure (PDB code: 6RO4) through structural super-imposition in UCSF Chimera\(^{55}\) and alignment with the two DNA strands of a single duplex from each structure. The ds/ss DNA junction was defined by the high-resolution DNA structure in the TFIIH-XPA complex and demarcated by the position of the XPA β-hairpin. The structure was subsequently manually refined in Coot\(^{57}\).
less otherwise stated. 100 µg XPF-ERCC1 heterodimer at a concentration of 1 mg/ml in 20 mM HEPES, pH 7.8, 10% Glycerol (w/v), 0.01% CHAPS (w/v), 150 mM NaCl, 1 mM TCEP, 0.5 mM EDTA was cross-linked using 1 mM disuccinimidyl sulfoxide (DSSO) (Thermo-Fisher) with mild shaking for 30 min at 37 °C. The reaction was quenched using a final concentration of 50 mM ammonium bicarbonate for a further 20 mins at 37 °C. To remove potential aggregates, gradient ultracentrifugation was employed using a 5-30% Glycerol gradient in 20 mM Hepes, 150 mM NaCl, mixed using a Gradient Master (BioComp), and centrifuged for 16 h at 4 °C at 40,000 RPM using a SW 55 Ti Rotor (Beckman Coulter)61. 100 µL fractions were collected and silver stained to identify fractions containing cross-linked non-aggregated XPF-ERCC1. Fractions containing cross-linked proteins were then pooled and buffer exchanged into 8 M urea using a Vivaspin 500, 30,000 molecular weight cut off (MWCO) PES filter (Sartorius, VS0122). Cysteine reduction was carried out using 2.5 mM TCEP for 30 min at 37 °C and alkylated in the dark using 5 mM iodoacetamide at room temperature. The urea was then buffer exchanged for 50 mM ammonium bicarbonate and proteins were proteolysed using trypsin (Promega) at 1:50 (w/w) trypsin:protein overnight at 37 °C. The solution was acidified using 2 % formic acid and peptides were the spun through the MWCO filter and desalted using in-house built STAGE tips made using Empore SPE C18 disks (3M, 66883-U). The eluent was then dried to completion. Peptides were reconstituted in 0.1% trifluoroacetic acid (TFA) and chromatographically resolved using an Ultimate 3000 RSILCnano (Dionex) HPLC. Peptides were first loaded onto an Acclaim PepMap 100 C18, 3 µm particle size, 100 Å pore size, 20 mm x 75 µm ID (Thermo Scientific, 164535) trap column using a loading buffer (2 % acetonitrile (MeCN) and 0.05 % TFA) with a flow rate of 7 µL/minute. Chromatographic separation was achieved using an EASY-Spray column, PepMap C18, 2 µm particles, 100 Å pore size, 500 mm x 75 µm ID (Thermo Scientific, ES803). The gradient utilised a flow of 0.3 µL/minute, starting at 98 % mobile A (0.1 % formic acid, 5 % dimethyl sulfoxide (DMSO) in H₂O) and 2 % mobile B (0.1 % formic acid, 75 % MeCN, 5 % DMSO and 19.9 % H₂O). After 6 min, mobile B was increased to 30 % over 69 min, to 45 % over 30 min, further increased to 90 % in 16 min and held for 4 min. Finally, Mobile B is reduced back to 5 % over 1 min for the rest of the acquisition. Data was acquired in real time over 140 minutes using an Orbitrap Fusion Lumos Trubrid mass spectrometer in positive, top speed mode with a cycle time of 5 s. The chromatogram (MS1) was captured using 60,000 resolution, a scan range of 375-1500 with a 50 ms maximum injection time, and 4e5 AGC target. Dynamic exclusion with repeat count 2, exclusion duration of 30 s, 20 ppm tolerance window was used, along with isotope exclusion, a minimum intensity exclusion of 2e4, charge state inclusion of 3-8 ions and peptide mono isotopic precursor selection. Precursors within a 1.6 mz isolation window were then fragmented using 25% normalised CID, 100 ms maximum injection time and 5e4 AGC target. Scans were recorded using 30,000 resolution in centroid mode, with a scan range of 120 – 2000 m/z. Spectra containing peaks with a mass difference of 31.9721 Da were further fragmented with a 30% normalised higher collision induced dissociation, using a 2 m/z isolation window, 150 ms maximum injection time and 2e4 AGC target. Four scans were recorded using an ion trap detection in rapid mode starting at 120 m/z.

**XL-MS data analysis**

Data processing was carried out using Proteome Discoverer Version 2.2 (Thermo Scientific) with the XlinkX node. The acquisition strategy was set to MS2_MS3 mode. The database comprised solely of the specific XPF and ERCC1 sequences. Trypsin was selected as the proteolytic enzyme allowing up to two missed cleavages with a minimal peptide length of five residues. Masses considered were in the range of 300-10000 Da. The precursor mass tolerance, FTMS fragment mass tolerance, and ITMS Fragment Mass Tolerance were set to 10 ppm, 20 ppm and 0.02 Da respectively. A static carbamidomethyl (+57.021 Da) modification was utilised for cysteine residues, with additional dynamic modifications considered including; amidated and hydrolysed DSSO (+142.050 Da and +176.014 Da, respectively) on lysine serine and threonine residues, oxidation (+15.995 Da) on methionine residues, and protein N-terminal acetylation (+42.011 Da). The FDR threshold was set to one with the strategy set to simple. The list of reported cross-linked spectral matches were manually examined and cross-links with spectra that did not contain acceptable b and y ion coverage were excluded.

**XPF-ERCC1-SLX4*NTD Complex Assembly**

cDNA encoding the SLX4*NTD (residues 1-758) (NCBI reference sequence: NM_032444) was shuttled into a pGEX-1 vector (Sigma). Recombinant baculoviruses expressing the SLX4*NTD were generated as previously described and used to infect 1x10⁶ SF21 cells (Thermo-Fisher) grown in SFIII media (Thermo-Fisher) and 10 µg/ml gentamycin (Life Technologies) at an MOI of 0.5. These cells were co-infected with XPF-ERCC1 expressing baculovirus at an MOI of 2. Cells were pelleted after 72 h and protein extracted as previously described for XPF-ERCC1. Following strep-tactin
affinity purification, the complex was purified using anion-exchange (HiTrap-Q, GE Healthcare) using a gradient of 150 mM NaCl to 500 mM NaCl over 20 ml of extract buffer minus protease inhibitors and Base-Muncher. This separated the SLX4\(^{NTD}\)-XPF-ERCC1 complex from unbound XPF-ERCC1. Fractions containing the SLX4\(^{NTD}\)-XPF-ERCC1 complex were pooled and concentrated prior to a final size exclusion chromatography (SEC) step using a Superose-6 increase column (GE Healthcare). Fractions containing both XPF and SLX4\(^{NTD}\) were identified via Western blot.

**Real-time fluorescence incision assay**

Fluorescently labelled stem-loop (SLF) DNA substrates, containing a 5′ 6-FAM fluorophore and 3′-BHQ1 quench, were purified by SEC (Superdex-200i, GE Healthcare) in assay buffer (5 mM HEPES, 10 % glycerol, 0.5 mM DTT, 1 mM MnCl\(_2\), and 40 mM NaCl). The purified substrates were then annealed by heating to 95 °C for 1 min followed by cooling to 4 °C and dispensed into the assay plate. Reactions were carried out in 384-well black, flat-bottomed microtitre plates (Corning 3854). Purified XPF-ERCC1 was buffer exchanged into assay buffer and 5 nM added to each in a total volume of 20 µl to initiate the endonuclease reaction. Fluorescence measurements were carried out using the CLARIOstar plate reader (BMG Labtech) using an excitation wavelength of 483 nm and an emission wavelength of 525 nm. 60 readings were collected at 30 s intervals and the linear response range for each substrate was used to determine the change in fluorescence per unit time. Kinetic parameters were calculated using the Michaelis–Menten equation in PRISM7. Experimental product release was quantified by plotting the relative fluorescence units (RFU) produced using the Michaelis–Menten equation in PRISM7.

**Data Availability**

The coordinates for the DNA-free XPF-ERCC1 structure are available in the PDB with the primary accession code 6SXA and EMBD entry code EMD-10337. The coordinates for the DNA-bound XPF-ERCC1 structure are available in the PDB with the primary accession code 6SXB and EMBD entry code EMD-10338.

**References**

1. Dehe, P.M. & Gaillard, P.H. Control of structure-specific endonucleases to maintain genome stability. Nat Rev Mol Cell Biol 18, 315-330 (2017).

2. Ciccia, A., McDonald, N. & West, S.C. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem 77, 259-87 (2008).

3. Faridounnia, M., Folkers, G.E. & Boelens, R. Function and Interactions of ERCC1-XPF in DNA Damage Response. Molecules 23(2018).

4. Marteijn, J.A., Lans, H., Vermeulen, W. & Hoeijmakers, J.H.J. Understanding nucleotide excision repair and its roles in cancer and ageing. Nature Reviews Molecular Cell Biology 15, 465 (2014).

5. Klein Douwel, D., Hoogenboom, W.S., Boonen, R.A.C.M. & Knipscheer, P. Recruitment and positioning determine the specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair. The EMBO Journal 36, 2034-2046 (2017).

6. Wyatt, H.D.M., Laister, R.C., Martin, S.R., Arrowsmith, C.H. & West, S.C. The SMX DNA Repair Tri-nuclease. Molecular Cell 65, 848-860.e11 (2017).

7. Wu, Y., Mitchell, T.R. & Zhu, X.D. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms. Mech Ageing Dev 129, 602-10 (2008).

8. Woodrick, J. et al. A new sub-pathway of long-patch base excision repair involving 5′ gap formation. The EMBO Journal 36, 1605-1622 (2017).

9. Al-Minawi, A.Z., Saleh-Gohari, N. & Helleday, T. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 36, 1-9 (2008).

10. Ahmed, A. et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28, 5082-92 (2008).

11. Bogliolo, M. et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet 92, 800-6 (2013).

12. Jaspers, N.G.J. et al. First Reported Patient with Human ERCC1 Deficiency Has Cerebro-Oculo-Facio-Skeletal Syndrome with a Mild Defect in Nucleotide Excision Repair and Severe Developmental Failure. The American Journal of Human Genetics 80, 457-466 (2007).

13. Kashiyama, K. et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am J Hum Genet 92, 807-19 (2013).

14. Niedernhofer, L.J. et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038 (2006).

15. Sijbers, A.M. et al. Xeroderma Pigmentosum Group F Caused by a Defect in a Structure-Specific DNA Repair Endonuclease. Cell 86, 811-822 (1996).

16. Fairman-Williams, M.E., Guenther, U.P. & Jankowsky, E. The specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair. EMBO J 36, 2034-2046 (2017).

17. Sgouros, J., Gaillard, P.H. & Wood, R.D. A relationship between DNA-repair/recombination nuclease family and archival helicases. Trends Biochem Sci 24, 95-17 (1999).

18. Gaillard, P.H. & Wood, R.D. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res 29, 872-9 (2001).

19. Klein Douwel, D., Hoogenboom, W.S., Boonen, R.A. & Knipscheer, P. Recruitment and positioning determine the specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair. EMBO J (2017).

20. Bowles, M. et al. Fluorescence-based incision assay for human XPF-ERCC1 activity identifies important elements of DNA junction recognition. Nucleic Acids Res 40, e101 (2012).

21. Enzlin, J.H. & Scharer, O.D. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J 21, 2045-53 (2002).

22. Orelli, B. et al. The XPA-binding domain of ERCC1 is re-
quired for nucleotide excision repair but not other DNA repair pathways. J Biol Chem 285, 3705-12 (2010).

23. O’Reilly, F.J. & Rappisilber, J. Cross-linking mass spectrometry: methods and applications in structural, molecular and systems biology. Nat Struct Mol Biol 25, 1000-1008 (2018).

24. Yan, L., Wu, H., Li, X., Gao, N. & Chen, Z. Structures of the ISWI-nucleosome complex reveal a conserved mechanism of chromatin remodeling. Nat Struct Mol Biol 26, 258-266 (2019).

25. Eustermann, S. et al. Structural basis for ATP-dependent chromatin remodeling by the INO80 complex. Nature 556, 386-390 (2018).

26. Holm, L. Benchmarking Fold Detection by DaliLite v.5. Bioinformatics (2019).

27. Yu, Q., Qu, K. & Modis, Y. Cryo-EM Structures of MDAX-dsRNA Filaments at Different Stages of ATP Hydrolysis. Mol Cell 72, 999-1012.e6 (2018).

28. Wu, B. et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDAX. Cell 152, 276-89 (2013).

29. Newman, M. et al. Structure of an XPF endonuclease with and without DNA suggests a model for substrate recognition. EMBO J 24, 895-905 (2005).

30. Tsodikov, O.V., Enzlin, J.H., Scharer, O.D. & Ellenberger, T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A 102, 11236-41 (2005).

31. Gwon, G.H. et al. Crystal structures of the structure-selective nuclease Mus81-Eme1 bound to flap DNA substrates. EMBO J 33, 1061-72 (2014).

32. Coulthard, R. et al. Architecture and DNA recognition elements of the Fanconi anemia FANCM-FAAP24 complex. Structure 21, 1648-58 (2013).

33. Tripkianes, K. et al. The structure of the human ERCC1/ XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 13, 1849-58 (2005).

34. Tsodikov, O.V. et al. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J 26, 4768-76 (2007).

35. Marin, M. et al. Functional Comparison of XPF Missense Mutations Associated to Multiple DNA Repair Disorders. Genes (Basel) 10(2019).

36. Matsumura, Y., Nishigori, C., Yagi, T., Imamura, S. & Takabe, H. Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. Hum Mol Genet 7, 969-74 (1998).

37. Sijbers, A.M. et al. Homozygous R788W point mutation of ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in epithelial ovarian cancers. Gynecol Oncol 153, 416-424 (2019).

38. McNeil, E.M. & Melton, D.W. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res 40, 9990-10004 (2012).

39. Kost, T.A. & Condreay, J.P. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr Opin Biotechnol 10, 428-33 (1999).

40. Zheng, S.Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods 14, 331-337 (2017).

41. Abdullah, U.B. et al. RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks. EMBO J 1605-12 (2004).

42. Rosenthal, P.B. & Henderson, R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol 333, 721-45 (2003).

43. Brown, A. et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Crystallogr D Biol Crystallogr 71, 136-53 (2015).

44. Topf, M. et al. Protein structure fitting and refinement guided by cryo-EM density. Structure 16, 295-307 (2008).

45. Afonine, P.V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 71, 531-544 (2018).

46. Williams, C.J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci 27, 293-315 (2018).

47. Kao, A. et al. Development of a novel cross-linking strategy for fast and accurate identification of cross-linked peptides of protein complexes. Mol Cell Proteomics 10, M110.002212 (2011).

48. de Graaf, S.C., Klykov, O., van den Toorn, H. & Schelter, M.A. Cross-ID: Analysis and Visualization of Complex XL-MS-Driven Protein Interaction Networks. J Proteome Res 18, 642-651 (2019).

49. Bessho, T., Sancar, A., Thompson, L.H. & Thelen, M.P. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem 272, 3833-7 (1997).

50. Kimanius, D., Forsberg, B.O., Scheres, S.H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. Elife 5(2016).

Acknowledgments
We thank members of the McDonald laboratory for helpful discussions and comments on the manuscript, in particular Amy Whittaker who also assisted in run-
ning the activity assays. We thank Andrew Purkiss of the structural biology science technology platform for assistance in refining the structures and Raffaella Carzaniga for EM training and support. We also thank Steve West for an anti-SLX4 antibody and Rick D Wood (MD Anderson Centre, Texas) for stimulating and encouraging the project in its early phases. We acknowledge the helpful advice and support of Peter Rosenthal on all aspects of cryo-electron microscopy. M.J. was funded by a Crick/UCL joint PhD studentship. N.Q.M. acknowledges that this work was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001115), the UK Medical Research Council (FC001115) and the Wellcome Trust (FC001115). EPM and FB acknowledge support from Cancer Research UK (C12209/A16749).

Author Contributions
M.J. cloned and purified XPF-ERCC1 complexes, processed all cryo-EM data, carried out activity assays and built the atomic models. M.J. and F.B. carried out EM grid preparations. F.B. and C.E assisted in grid screening, A.N and P.R. ran the data collections. F.B. and E.P.M. assisted the XPF-ERCC1 single particle reconstruction and interpretation. D.B. assisted in model refinement and validation. M.B. for supporting the project in its early phases. A.B. carried out the XL-MS. M.J. and N.Q.M. designed the study, interpreted the results and wrote the paper.

Competing Financial Interests
None